TABLE 1

Tumors in Field of View

Patient no.LocalizationNo. of tumorsVolume (cm3)Tumor PD-L1 expression from IHCTotal PD-L1 in slide (%)Model preference AICVT (mL⋅cm−3)Vb (%)
2Lung RLL177.7+ (90%)25STR4.010
2LN 10R24.1NASTR4.131
2LN 4R35.7NASTR4.814
2Lung LLL486.0+ (95%)64STR2.517
3Lung LLL159.1− (0%)2TTI0.617
6Lung RUL12.3NASTR0.78
7LN AXIL 116.4NASTR0.77
7LN N7224.7NATTI2.320
7LN AXIL 2314.5− (0%)3STR0.910
8Lung RUL16.4NASTR0.611
8Humerus218.0NATTI0.57
9Lung RUL168.5− (0%)5STR0.922
11Lung hilar mass26.5NASTR1.522
12Lung LLL12.4+ (10%)10TTI1.316
12LN 10 L21.2NATTI1.434
12LN 11 L32.7NASTR2.334
13Pancreas18.8NATTI0.411
13Pancreas226.6NATTI0.515
  • RLL = right upper lobe; LN = lymph node; LLL = left lower lobe; RUL = right upper lobe; AXIL = axillary; IHC = immunohistochemistry; NA = not applicable; AIC = Akaike information criterion; STR = single-tissue reversible; TTI = 2-tissue irreversible; Vb = blood volume fraction.